Arno Therapeutics', AR12 and AR42 were treatment consideration for NF2. Following Phase 0 mice trials, AR42 was determined to be more likely to be effective. AR12 did not go further in clinical trials.
Other Names |
AR12, OSU-HDAR12, HDAR42 |
---|---|
Pharmaceutical Company | Arno Therapeutics |
Prescription Information | Arno Therapeutics - Drug Description |
Expectation | Change in Meningioma and Schwannoma in CNS |
Inhibitor | HDAC - Histone deacetylase inhibitors (HDACi), pan-HDAC inhibitor |
---|